Qianjiang Yongan Pharmaceutical Co Ltd (002365) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qianjiang Yongan Pharmaceutical Co Ltd (002365) has a cash flow conversion efficiency ratio of 0.029x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥58.18 Million ≈ $8.51 Million USD) by net assets (CN¥2.02 Billion ≈ $294.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Qianjiang Yongan Pharmaceutical Co Ltd (002365) net asset quality to measure how much of total assets are equity-financed.
Qianjiang Yongan Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Qianjiang Yongan Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Qianjiang Yongan Pharmaceutical Co Ltd (002365) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Qianjiang Yongan Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qianjiang Yongan Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tekla Life Sciences Investors
NYSE:HQL
|
-0.002x |
|
Laurent-Perrier
PA:LPE
|
0.002x |
|
Guangzhou Grandbuy Co Ltd
SHE:002187
|
0.021x |
|
Huamei Holding
SHE:000607
|
0.037x |
|
Nanjing Railway New Technology Co.Ltd.
SHE:301016
|
-0.015x |
|
Hongsheng Heat Exchanger Mnfg
SHG:603090
|
0.047x |
|
More Provident Funds
TA:MPP
|
-0.116x |
|
ATRenew Inc DRC
NYSE:RERE
|
0.006x |
Annual Cash Flow Conversion Efficiency for Qianjiang Yongan Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Qianjiang Yongan Pharmaceutical Co Ltd from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see 002365 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.04 Billion ≈ $298.82 Million |
CN¥105.71 Million ≈ $15.47 Million |
0.052x | -56.59% |
| 2023-12-31 | CN¥2.05 Billion ≈ $299.73 Million |
CN¥244.26 Million ≈ $35.74 Million |
0.119x | -35.25% |
| 2022-12-31 | CN¥2.10 Billion ≈ $307.74 Million |
CN¥387.28 Million ≈ $56.67 Million |
0.184x | +253.98% |
| 2021-12-31 | CN¥1.96 Billion ≈ $286.37 Million |
CN¥101.81 Million ≈ $14.90 Million |
0.052x | -54.34% |
| 2020-12-31 | CN¥1.81 Billion ≈ $265.42 Million |
CN¥206.66 Million ≈ $30.24 Million |
0.114x | -21.20% |
| 2019-12-31 | CN¥1.66 Billion ≈ $242.43 Million |
CN¥239.55 Million ≈ $35.05 Million |
0.145x | -26.06% |
| 2018-12-31 | CN¥1.61 Billion ≈ $235.00 Million |
CN¥314.02 Million ≈ $45.95 Million |
0.196x | +33.26% |
| 2017-12-31 | CN¥1.34 Billion ≈ $196.77 Million |
CN¥197.32 Million ≈ $28.87 Million |
0.147x | +104.33% |
| 2016-12-31 | CN¥1.18 Billion ≈ $172.25 Million |
CN¥84.53 Million ≈ $12.37 Million |
0.072x | +13.87% |
| 2015-12-31 | CN¥1.12 Billion ≈ $163.82 Million |
CN¥70.61 Million ≈ $10.33 Million |
0.063x | +262.73% |
| 2014-12-31 | CN¥1.11 Billion ≈ $162.12 Million |
CN¥19.26 Million ≈ $2.82 Million |
0.017x | -70.50% |
| 2013-12-31 | CN¥1.08 Billion ≈ $158.02 Million |
CN¥63.65 Million ≈ $9.31 Million |
0.059x | -8.84% |
| 2012-12-31 | CN¥1.09 Billion ≈ $160.11 Million |
CN¥70.75 Million ≈ $10.35 Million |
0.065x | -25.14% |
| 2011-12-31 | CN¥1.06 Billion ≈ $154.57 Million |
CN¥91.23 Million ≈ $13.35 Million |
0.086x | +98.86% |
| 2010-12-31 | CN¥1.01 Billion ≈ $148.46 Million |
CN¥44.06 Million ≈ $6.45 Million |
0.043x | -61.35% |
| 2009-12-31 | CN¥324.17 Million ≈ $47.44 Million |
CN¥36.43 Million ≈ $5.33 Million |
0.112x | -81.62% |
| 2008-12-31 | CN¥259.12 Million ≈ $37.92 Million |
CN¥158.47 Million ≈ $23.19 Million |
0.612x | +91.78% |
| 2007-12-31 | CN¥191.53 Million ≈ $28.03 Million |
CN¥61.08 Million ≈ $8.94 Million |
0.319x | +7.60% |
| 2006-12-31 | CN¥104.99 Million ≈ $15.36 Million |
CN¥31.11 Million ≈ $4.55 Million |
0.296x | -- |
About Qianjiang Yongan Pharmaceutical Co Ltd
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmace… Read more